341 related articles for article (PubMed ID: 31556015)
1. Efficacy of initial temozolomide for high-risk low grade gliomas in a phase II AINO (Italian Association for Neuro-Oncology) study: a post-hoc analysis within molecular subgroups of WHO 2016.
Rudà R; Pellerino A; Pace A; Carapella CM; Dealis C; Caroli M; Faedi M; Bello L; Migliore E; Marchese G; Bertero L; Cassoni P; Soffietti R
J Neurooncol; 2019 Oct; 145(1):115-123. PubMed ID: 31556015
[TBL] [Abstract][Full Text] [Related]
2. Observation versus radiotherapy with or without temozolomide in postoperative WHO grade II high-risk low-grade glioma: a retrospective cohort study.
Wang J; Yan L; Ai P; He Y; Guan H; Wei Z; He L; Mu X; Liu Y; Peng X
Neurosurg Rev; 2021 Jun; 44(3):1447-1455. PubMed ID: 32529528
[TBL] [Abstract][Full Text] [Related]
3. Long-term impact of temozolomide on 1p/19q-codeleted low-grade glioma growth kinetics.
Izquierdo C; Alentorn A; Idbaih A; Simó M; Kaloshi G; Ricard D; Barritault M; Meyronet D; Bruna J; Honnorat J; Delattre JY; Ducray F
J Neurooncol; 2018 Feb; 136(3):533-539. PubMed ID: 29143276
[TBL] [Abstract][Full Text] [Related]
4. Association of MGMT Promoter Methylation With Survival in Low-grade and Anaplastic Gliomas After Alkylating Chemotherapy.
Kinslow CJ; Mercurio A; Kumar P; Rae AI; Siegelin MD; Grinband J; Taparra K; Upadhyayula PS; McKhann GM; Sisti MB; Bruce JN; Canoll PD; Iwamoto FM; Kachnic LA; Yu JB; Cheng SK; Wang TJC
JAMA Oncol; 2023 Jul; 9(7):919-927. PubMed ID: 37200021
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide.
Wahl M; Phillips JJ; Molinaro AM; Lin Y; Perry A; Haas-Kogan DA; Costello JF; Dayal M; Butowski N; Clarke JL; Prados M; Nelson S; Berger MS; Chang SM
Neuro Oncol; 2017 Feb; 19(2):242-251. PubMed ID: 27571885
[TBL] [Abstract][Full Text] [Related]
6. A 25-year retrospective, single center analysis of 343 WHO grade II/III glioma patients: implications for grading and temozolomide therapy.
Steidl E; Filipski K; Zeiner PS; Wagner M; Fokas E; Forster MT; Ronellenfitsch MW; Divé I; Steinbach JP; Harter PN; Bähr O
J Cancer Res Clin Oncol; 2021 Aug; 147(8):2373-2383. PubMed ID: 33538917
[TBL] [Abstract][Full Text] [Related]
7. Radiation and chemotherapy for high-risk lower grade gliomas: Choosing between temozolomide and PCV.
McDuff SGR; Dietrich J; Atkins KM; Oh KS; Loeffler JS; Shih HA
Cancer Med; 2020 Jan; 9(1):3-11. PubMed ID: 31701682
[TBL] [Abstract][Full Text] [Related]
8. Neuro-radiological characteristics of adult diffuse grade II and III insular gliomas classified according to WHO 2016.
Compes P; Tabouret E; Etcheverry A; Colin C; Appay R; Cordier N; Mosser J; Chinot O; Delingette H; Girard N; Dufour H; Metellus P; Figarella-Branger D
J Neurooncol; 2019 May; 142(3):511-520. PubMed ID: 30756272
[TBL] [Abstract][Full Text] [Related]
9. Upfront Therapy of Aggressive/High-Risk Low-Grade Glioma: Single-Institution Outcome Analysis of Temozolomide-Based Radio-Chemotherapy and Adjuvant Chemotherapy.
Anand S; Chatterjee A; Gupta T; Panda P; Moiyadi A; Epari S; Patil V; Krishnatry R; Goda JS; Jalali R
World Neurosurg; 2021 Oct; 154():e176-e184. PubMed ID: 34245877
[TBL] [Abstract][Full Text] [Related]
10. Imaging correlates for the 2016 update on WHO classification of grade II/III gliomas: implications for IDH, 1p/19q and ATRX status.
Delfanti RL; Piccioni DE; Handwerker J; Bahrami N; Krishnan A; Karunamuni R; Hattangadi-Gluth JA; Seibert TM; Srikant A; Jones KA; Snyder VS; Dale AM; White NS; McDonald CR; Farid N
J Neurooncol; 2017 Dec; 135(3):601-609. PubMed ID: 28871469
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and patient-reported outcomes with dose-intense temozolomide in patients with newly diagnosed pure and mixed anaplastic oligodendroglioma: a phase II multicenter study.
Ahluwalia MS; Xie H; Dahiya S; Hashemi-Sadraei N; Schiff D; Fisher PG; Chamberlain MC; Pannullo S; Newton HB; Brewer C; Wood L; Prayson R; Elson P; Peereboom DM
J Neurooncol; 2015 Mar; 122(1):111-9. PubMed ID: 25534576
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: long term results of RTOG BR0131.
Vogelbaum MA; Hu C; Peereboom DM; Macdonald DR; Giannini C; Suh JH; Jenkins RB; Laack NN; Brachman DG; Shrieve DC; Souhami L; Mehta MP
J Neurooncol; 2015 Sep; 124(3):413-20. PubMed ID: 26088460
[TBL] [Abstract][Full Text] [Related]
13. Impact of 1p/19q codeletion and histology on outcomes of anaplastic gliomas treated with radiation therapy and temozolomide.
Speirs CK; Simpson JR; Robinson CG; DeWees TA; Tran DD; Linette G; Chicoine MR; Dacey RG; Rich KM; Dowling JL; Leuthardt EC; Zipfel GJ; Kim AH; Huang J
Int J Radiat Oncol Biol Phys; 2015 Feb; 91(2):268-76. PubMed ID: 25636755
[TBL] [Abstract][Full Text] [Related]
14. Concurrent and Adjuvant Temozolomide for Newly Diagnosed Grade III Gliomas without 1p/19q Co-deletion: A Randomized, Open-Label, Phase 2 Study (KNOG-1101 Study).
Hwang K; Kim TM; Park CK; Chang JH; Jung TY; Kim JH; Nam DH; Kim SH; Yoo H; Hong YK; Kim EY; Lee DE; Joo J; Kim YJ; Choe G; Choi BS; Kang SG; Kim JH; Kim CY
Cancer Res Treat; 2020 Apr; 52(2):505-515. PubMed ID: 31671938
[TBL] [Abstract][Full Text] [Related]
15.
Zhao K; Yu P; Xue Z; Liu J; Yao A; Zhao Y; Yang F; Tian J; Xu B
Acad Radiol; 2020 Jul; 27(7):e159-e167. PubMed ID: 31607471
[TBL] [Abstract][Full Text] [Related]
16. Malignant Transformation of Molecularly Classified Adult Low-Grade Glioma.
Tom MC; Park DYJ; Yang K; Leyrer CM; Wei W; Jia X; Varra V; Yu JS; Chao ST; Balagamwala EH; Suh JH; Vogelbaum MA; Barnett GH; Prayson RA; Stevens GHJ; Peereboom DM; Ahluwalia MS; Murphy ES
Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):1106-1112. PubMed ID: 31461674
[TBL] [Abstract][Full Text] [Related]
17. Eighty percent survival rate at 15 years for 1p/19q co-deleted oligodendroglioma treated with upfront chemotherapy irrespective of tumor grade.
Iwadate Y; Matsutani T; Hara A; Hirono S; Ikegami S; Kobayashi M; Ito D; Kawauchi D; Horiguchi K; Tamiya A; Higuchi Y
J Neurooncol; 2019 Jan; 141(1):205-211. PubMed ID: 30565028
[TBL] [Abstract][Full Text] [Related]
18. Radio-chemotherapy improves survival in IDH-mutant, 1p/19q non-codeleted secondary high-grade astrocytoma patients.
Juratli TA; Lautenschläger T; Geiger KD; Pinzer T; Krause M; Schackert G; Krex D
J Neurooncol; 2015 Sep; 124(2):197-205. PubMed ID: 26033545
[TBL] [Abstract][Full Text] [Related]
19. Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma.
Thomas AA; Abrey LE; Terziev R; Raizer J; Martinez NL; Forsyth P; Paleologos N; Matasar M; Sauter CS; Moskowitz C; Nimer SD; DeAngelis LM; Kaley T; Grimm S; Louis DN; Cairncross JG; Panageas KS; Briggs S; Faivre G; Mohile NA; Mehta J; Jonsson P; Chakravarty D; Gao J; Schultz N; Brennan CW; Huse JT; Omuro A
Neuro Oncol; 2017 Oct; 19(10):1380-1390. PubMed ID: 28472509
[TBL] [Abstract][Full Text] [Related]
20. Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort.
Tabouret E; Nguyen AT; Dehais C; Carpentier C; Ducray F; Idbaih A; Mokhtari K; Jouvet A; Uro-Coste E; Colin C; Chinot O; Loiseau H; Moyal E; Maurage CA; Polivka M; Lechapt-Zalcman E; Desenclos C; Meyronet D; Delattre JY; Figarella-Branger D;
Acta Neuropathol; 2016 Oct; 132(4):625-34. PubMed ID: 27573687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]